Skip to main content

Soren M. Bentzen, PhD, DMSc

Academic Title:


Primary Appointment:

Epidemiology & Public Health

Secondary Appointment(s):

Radiation Oncology

Administrative Title:

Division Director, Biostatistics And Bioinformatics

Additional Title:

Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Biostatistics Shared Service, Director of the Biostatistics Core of the Institute of Clinical and Translational Research (ICTR)


HH 109D

Phone (Primary):




Education and Training

D.M.Sc. (Doctor of Medical Science), Medicine/Clinical Radiobiology, U of Aarhus, Denmark, 1994

Ph.D. in Medicine/Medical Physics, University of Aarhus, Denmark, 1986

M.Sc. in Physics, University of Aarhus, Denmark, 1981

B.Sc. in Physics & Mathematics, University of Aarhus, Denmark, 1978.


Søren M. Bentzen, MSc, PhD, DMSc, Professor, Director of the Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine since 2013. Dr. Bentzen also serves as Director of the Biostatistics Shared Service, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, and as Director of the Biostatistics Core of the University of Maryland Baltimore Institute of Clinical and Translational Research (ICTR). He is also an Adjunct Professor of Radiobiology and Medical Physics, University of Copenhagen, Denmark. His previous appointments include MD Anderson Cancer Center (1987-1988), Danish Cancer Society/Aarhus University (1988-1997), Gray Laboratory/Mount Vernon Hospital, London (1998-2004), and University of Wisconsin School of Medicine and Public Health (2005-2013) where he was a professor of Human Oncology and held affiliate faculty positions in the departments of Biostatistics & Medical Informatics and in Medical Physics.

Dr. Bentzen received a MSc in physics and mathematics (1981), a PhD in medical image analysis (1986), and a DMSc (doctor of medical science) in quantitative clinical radiobiology (1994), all from Aarhus University, Denmark. He has published >540 original papers and book chapters, and has presented >390 invited lectures. He currently serves on 10 international cancer journal editorial boards. His research has been recognized by 34 awards and honors, including the ASTRO Gold Medal (2017), ESTRO Breuer Gold Medal (2003), the MD Anderson Distinguished Alumnus Award (2008), and Honorary Life Memberships of the Association of Radiation Oncologists of India (2008), the Belgian Society for Therapeutic Radiology and Oncology (2009), and the German Society for Radiation Oncology (2020). He was inducted as a Fellow of the American Society of Radiation Oncology (FASTRO) in 2018, and selected as an Honorary Fellow of the British Institute of Radiology in 2023. He held an Honorary Professorship at University College London (2000-2005) and was a Visiting Statistician to the Medical Research Council Clinical Trials Office, London, UK (1998-2004).

Dr. Bentzen is currently the principal investigator of a randomized controlled phase III trial of resource sparing radiation therapy for locally-advanced squamous cell carcinoma of the head and neck, sponsored by the International Atomic Energy Agency; member of the Head and Neck Cancer Steering Committee of the National Cancer Institute (NCI); founding member of the Steering Committee of the International Radiogenomics Consortium; member of the UICC Global Task Force on Radiotherapy for Cancer Control; member of the Board of Directors of the International Commission on Radiation Units. Dr. Bentzen was one of the leaders of the QUANTEC (Quantitative Analyses of Normal Tissue Effects in the Clinic) initiative (2007-2010) and serves as a member of the PENTEC (Pediatric Normal Tissue Effects in the Clinic) steering committee (2016-present). He was a member of the ASTRO Task Forces to develop evidence-based guidelines on the appropriate fractionation for whole breast irradiation (2009-2010) and for localized prostate cancer (2016-2018). He has served as chair or member of 17 (seven currently active) Independent Data and Safety Monitoring Committees or Trial Steering Committees. Served as co-chair for Translational Research for two RTOG phase III trials.

His main research interests include bioeffect modeling; biomathematics; applied biostatistics; clinical trial design; evidence-based medicine; late effects of radiotherapy; clinical radiobiology; integration of data from genomics, proteomics, and molecular imaging into novel therapeutic strategies.

In addition to his role as Director of the Biostatistics Shared Service, Dr. Bentzen is a member of the Experimental Therapeutics Program within the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center Program in Oncology. He collaborates with both basic and clinical researchers, aiming for the rapid translation of discoveries from the laboratory to the clinic. Dr. Bentzen’s research focuses on three broad fields: normal-tissue radiation biology; biomarkers, including genomic and imaging biomarkers, in predictive oncology; and the pre-clinical and clinical development of drug-radiation combinations.

Additional Publication Citations

For my up-to-date full PubMed bibliography click here.

Buffa FM, Bentzen SM, Daley FM, Dische S, Saunders MI, Richman PI, Wilson GD. 2004. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 10:3745-3754.

Trotti A, Bentzen SM. 2004. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22:19-22.

Bentzen SM. 2005. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6:112-117.

Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, Wilson GD. 2005. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560-5567.

Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, van den Bogaert W. 2005. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol 75:355-365.

Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J. 2005. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.Radiother Oncol 77:18-24.

Bentzen SM. 2006. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 6:702-713.

Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL. 2006. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735.

Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J, Bentzen SM, Yarnold JR. 2006. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 7:467-471.

Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. 2006. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24:45-51.

Bentzen SM, Harari PM, Bernier J. 2007. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4:172-180.

Bentzen SM, Trotti A. 2007. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25:4096-4103.

Li J, Bentzen SM, Renschler M, Mehta MP. 2007. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260-1266.

Short SC, Buffa FM, Bourne S, Koritzinsky M, Wouters BG, Bentzen SM. 2007. Dose- and time-dependent changes in gene expression in human glioma cells after low radiation doses. Radiat Res 168:199-208.

Tang PA, Bentzen SM, Chen EX, Siu LL. 2007. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568.

Bentzen SM. 2008. Radiation oncology health technology assessment: the best is the enemy of the good. Nat Clin Pract Oncol 5:563.

Bentzen SM. 2008. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol 18:75-88.

Bentzen SM. 2008. Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol 86:142-147.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. 2008. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371:1098-1107.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. 2008. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 9:331-341.

Li J, Bentzen SM, Li J, Renschler M, Mehta MP. 2008. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 71:64-70.

Bernier J, Bentzen SM, Vermorken JB. 2009. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6:266-277.

Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, Ten Haken RK, Yorke ED. 2010. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76:S3-9.

Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, Rosenstein BS. 2010. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys 76:S145-150.

Haviland JS, Yarnold JR, Bentzen SM. 2010. Hypofractionated radiotherapy for breast cancer. N Engl J Med 362:1843-1844.

Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. 2010. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 28:4912-4918.

Bentzen SM, Gregoire V. 2011. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 21:101-110.

Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, McCormick B, McQueen JR, Pierce LJ, Powell SN, Recht A, Taghian AG, Vicini FA, White JR, Haffty BG. 2011. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 81:59-68.

Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM. 2012. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13:65-77.

Barnett GC, West CM, Coles CE, Pharoah PD, Talbot CJ, Elliott RM, Tanteles GA, Symonds RP, Wilkinson JS, Dunning AM, Burnet NG,Bentzen SM. 2012. Standardized Total Average Toxicity score: a scale- and grade-independent measure of late radiotherapy toxicity to facilitate pooling of data from different studies. Int J Radiat Oncol Biol Phys 82:1065-1074.

Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Jr., Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. 2012. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys 83:782-790.

Bentzen SM, Dorr W, Gahbauer R, Howell RW, Joiner MC, Jones B, Jones DT, van der Kogel AJ, Wambersie A, Whitmore G. 2012. Bioeffect modeling and equieffective dose concepts in radiation oncology--terminology, quantities and units. Radiother Oncol 105:266-268.

Brodin NP, Vogelius IR, Maraldo MV, Munck af Rosenschold P, Aznar MC, Kiil-Berthelsen A, Nilsson P, Bjork-Eriksson T, Specht L,Bentzen SM. 2012. Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 118:5432-5440.

Appelt AL, Vogelius IR, Bentzen SM. 2013. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clin Oncol (R Coll Radiol) 25:147-152.

Brodin NP, Vogelius IR, Bjork-Eriksson T, Munck af Rosenschold P, Bentzen SM. 2013. Modeling freedom from progression for standard-risk medulloblastoma: a mathematical tumor control model with multiple modes of failure. Int J Radiat Oncol Biol Phys 87:422-429.

Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D. 2013. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429-1437.

Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tome WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM. 2013. Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol 31:4343-4348.

Hong JC, Kruser TJ, Gondi V, Mohindra P, Cannon DM, Harari PM, Bentzen SM. 2013. Risk of cerebrovascular events in elderly patients after radiation therapy versus surgery for early-stage glottic cancer. Int J Radiat Oncol Biol Phys 87:290-296.

Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ, Jr., Bentzen SM, Okunieff P, Coleman CN, Dicker AP. 2013. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst 105:11-24.

Vogelius IR, Bentzen SM. 2013. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85:89-94.

Vogelius IR, Hakansson K, Due AK, Aznar MC, Berthelsen AK, Kristensen CA, Rasmussen J, Specht L, Bentzen SM. 2013. Failure-probability driven dose painting. Med Phys 40: 081717.

Kerns SL, de Ruysscher D, Andreassen CN, Azria D, Barnett GC, Chang-Claude J, Davidson S, Deasy JO, Dunning AM, Ostrer H, Rosenstein BS, West CM, Bentzen SM. STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol. 2014 Jan;110(1):182-8.

Haviland JS, A'Hern R, Bentzen SM, Whelan T, Bliss JM. Radiotherapy for breast cancer, the TARGIT-A trial. Lancet. 2014 May 17;383(9930):1716-7.

Rasmussen GB, Vogelius IR, Rasmussen JH, Schumaker L, Ioffe O, Cullen K, Fischer BM, Therkildsen MH, Specht L, Bentzen SM. Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. Acta Oncol. 2015;54(9):1408-15. doi: 10.3109/0284186X.2015.1062539. Epub 2015 Aug 9. PubMed PMID: 26256482.

Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016 Apr;16(4):234-49. doi: 10.1038/nrc.2016.18. Epub 2016 Mar 18. Review. PubMed PMID: 27009394.

Andreassen CN, Rosenstein BS, Kerns SL, Ostrer H, De Ruysscher D, Cesaretti JA, Barnett GC, Dunning AM, Dorling L, West CML, Burnet NG, Elliott R, Coles C, Hall E, Fachal L, Vega A, Gómez-Caamaño A, Talbot CJ, Symonds RP, De Ruyck K, Thierens H, Ost P, Chang-Claude J, Seibold P, Popanda O, Overgaard M, Dearnaley D, Sydes MR, Azria D, Koch CA, Parliament M, Blackshaw M, Sia M, Fuentes-Raspall MJ, Ramon Y Cajal T, Barnadas A, Vesprini D, Gutiérrez-Enríquez S, Mollà M, Díez O, Yarnold JR, Overgaard J, Bentzen SM, Alsner J; International Radiogenomics Consortium (RgC). Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. Radiother Oncol. 2016 Dec;121(3):431-439. doi: 10.1016/j.radonc.2016.06.017. Epub 2016 Jul 18. PubMed PMID: 27443449; PubMed Central PMCID: PMC5559879.

Haviland JS, Bentzen SM, Bliss JM, Yarnold JR; START Trial Management Group. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiother Oncol. 2016 Dec;121(3):420-423. doi: 10.1016/j.radonc.2016.08.027. Epub 2016 Sep 22. PubMed PMID: 27666929.

Nowak RG, Ambulos NP, Schumaker LM, Mathias TJ, White RA, Troyer J, Wells D, Charurat ME, Bentzen SM, Cullen KJ. Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array.Virol J. 2017 Jun 13;14(1):112. doi: 10.1186/s12985-017-0771-z. PubMed PMID:28610586; PubMed Central PMCID: PMC5470268.

Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB 2nd, Feigenberg SJ, Mohindra P. Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer. Lung Cancer. 2017 Dec;114:44-49. doi: 10.1016/j.lungcan.2017.10.016. Epub 2017
Nov 2. Erratum in: Lung Cancer. 2017 Dec 27;:. PubMed PMID: 29173764.

Ntiri SO, Klyushnenkova EN, Bentzen SM. Outcomes of a Community-based Breast Cancer Screening Program in Baltimore City. J Health Care Poor Underserved. 2018;29(3):898-913. doi: 10.1353/hpu.2018.0067. PubMed PMID: 30122671.

Vogelius IR, Bentzen SM. Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865. doi: 10.1016/j.ijrobp.2017.12.011. Epub 2017 Dec 15. PubMed PMID: 29485063.

Nygård L, Vogelius IR, Fischer BM, Kjær A, Langer SW, Aznar MC, Persson GF, Bentzen SM. A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Apr;13(4):559-567. doi: 10.1016/j.jtho.2017.12.011. PubMed PMID: 29355615.

Lühr A, von Neubeck C, Pawelke J, Seidlitz A, Peitzsch C, Bentzen SM, Bortfeld T, Debus J, Deutsch E, Langendijk JA, Loeffler JS, Mohan R, Scholz M, Sørensen BS, Weber DC, Baumann M, Krause M."Radiobiology of Proton Therapy": Results of an international expert workshop. Radiother Oncol. 2018 Jul;128(1):56-67. doi: 10.1016/j.radonc.2018.05.018. Epub 2018 Jun 1. Review. PubMed PMID: 29861141.

Pinnow E, Amr S, Bentzen SM, Brajovic S, Hungerford L, St George DM, Dal Pan G. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014. Clin Pharmacol Ther. 2018 Aug;104(2):390-400. doi: 10.1002/cpt.944. Epub 2017 Dec 20. PubMed PMID: 29266187.

Nowak RG, Bentzen SM, Ravel J, Crowell TA, Dauda W, Ma B, Liu H, Blattner WA, Baral SD, Charurat ME. Anal Microbial Patterns and Oncogenic Human Papillomavirus in a Pilot Study of Nigerian Men Who Have Sex with Men at Risk for or Living with HIV. AIDS Res Hum Retroviruses. 2018 Oct 17. doi: 10.1089/AID.2018.0158. [Epub ahead of print] PubMed PMID: 30215262.

Zandberg DP, Cullen K, Bentzen SM, Goloubeva OG. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. Oral Oncol. 2018 Nov;86:132-140. doi: 10.1016/j.oraloncology.2018.09.023. Epub 2018 Sep 21. PubMed PMID: 30409293.

Modiri A, Stick LB, Rice SR, Rechner LA, Vogelius IR, Bentzen SM, Sawant A. Individualized estimates of overall survival in radiation therapy plan optimization - A concept study. Med Phys. 2018 Nov;45(11):5332-5342. doi: 10.1002/mp.13211. Epub 2018 Oct 17. PubMed PMID: 30246353.

Rice SR, Bentzen SM, Hanna A, Choi E, Boggs DH, Kwok Y, Hyder J, Feigenberg SJ, Regine WF, Woodworth GF, Eisenberg HM, Yu C, Biggins TF, Barnholtz-Sloan JS, Sperduto PW, Weltman E, Mehta MP. Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. J Neurooncol. 2018 Nov;140(2):341-349. doi: 10.1007/s11060-018-2958-6. Epub 2018 Aug 21. PubMed PMID: 30132164.

Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen SM, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol. 2018 Oct 11;36(34):JCO1801097. doi: 10.1200/JCO.18.01097. Epub ahead of print. PMID: 30307776; PMCID: PMC6269129.

Vyfhuis MAL, Bentzen SM, Molitoris JK, Diwanji T, Badiyan S, Grover S, Adebamowo CA, Simone CB 2nd, Mohindra P. Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients. Clin Lung Cancer. 2019 Jul;20(4):248-257.e4. doi: 10.1016/j.cllc.2019.02.015. Epub 2019 Feb 28. PMID: 30910573.

Zandberg DP, Tallon LJ, Nagaraj S, Sadzewicz LK, Zhang Y, Strome MB, Zhao XE, Vavikolanu K, Zhang X, Papadimitriou JC, Hubbard FA, Bentzen SM, Strome SE, Fraser CM. Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. Head Neck. 2019 Aug;41(8):2514-2524. doi: 10.1002/hed.25719. Epub 2019 Mar 14. PMID: 30869813.

Morgan DJ, Bame B, Zimand P, Dooley P, Thom KA, Harris AD, Bentzen SM, Ettinger W, Garrett-Ray SD, Tracy JK, Liang Y. Assessment of Machine Learning vs Standard Prediction Rules for Predicting Hospital Readmissions. JAMA Netw Open. 2019 Mar 1;2(3):e190348. doi: 10.1001/jamanetworkopen.2019.0348. PMID: 30848808; PMCID: PMC6484642.

Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM, Bentzen SM, Specht L, Kristensen CA, von Buchwald C, Wessel I, Friborg J. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer. 2019 May;120(10):1003-1006. doi: 10.1038/s41416-019-0449-y. Epub 2019 Apr 10. PMID: 30967647; PMCID: PMC6734649.

DeCesaris CM, Rice SR, Bentzen SM, Jatczak J, Mishra MV, Nichols EM. Quantification of Acute Skin Toxicities in Patients With Breast Cancer Undergoing Adjuvant Proton versus Photon Radiation Therapy: A Single Institutional Experience. Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1084-1090. doi: 10.1016/j.ijrobp.2019.04.015. Epub 2019 Apr 24. PMID: 31028831.

Kerns SL, Fachal L, Dorling L, Barnett GC, Baran A, Peterson DR, Hollenberg M, Hao K, Narzo AD, Ahsen ME, Pandey G, Bentzen SM, Janelsins M, Elliott RM, Pharoah PDP, Burnet NG, Dearnaley DP, Gulliford SL, Hall E, Sydes MR, Aguado-Barrera ME, Gómez-Caamaño A, Carballo AM, Peleteiro P, Lobato-Busto R, Stock R, Stone NN, Ostrer H, Usmani N, Singhal S, Tsuji H, Imai T, Saito S, Eeles R, DeRuyck K, Parliament M, Dunning AM, Vega A, Rosenstein BS, West CML. Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. J Natl Cancer Inst. 2020 Feb 1;112(2):179-190. doi: 10.1093/jnci/djz075.

Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA. The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):698-712. doi: 10.1016/j.ijrobp.2019.07.026. Epub 2019 Aug 2. PMID: 31381960.

Vittrup AS, Kirchheiner K, Fokdal LU, Bentzen SM, Nout RA, Pötter R, Tanderup K. Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):957-967. doi: 10.1016/j.ijrobp.2019.08.040. Epub 2019 Aug 27. PMID: 31470092.

Vogelius IR, Petersen J, Bentzen SM. Harnessing data science to advance radiation oncology. Mol Oncol. 2020 Jul;14(7):1514-1528. doi: 10.1002/1878-0261.12685. Epub 2020 May 18. PMID: 32255249; PMCID: PMC7332210.

Griffin RJ, Ahmed MM, Amendola B, Belyakov O, Bentzen SM, Butterworth KT, Chang S, Coleman CN, Djonov V, Formenti SC, Glatstein E, Guha C, Kalnicki S, Le QT, Loo BW Jr, Mahadevan A, Massaccesi M, Maxim PG, Mohiuddin M, Mohiuddin M, Mayr NA, Obcemea C, Petersson K, Regine W, Roach M, Romanelli P, Simone CB 2nd, Snider JW, Spitz DR, Vikram B, Vozenin MC, Abdel-Wahab M, Welsh J, Wu X, Limoli CL. Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):766-778.
doi: 10.1016/j.ijrobp.2020.03.028. Epub 2020 Apr 13. PMID: 32298811.

Nygård L, Ahlborn LB, Persson GF, Chandrananda D, Langer JW, Fischer BM, Langer SW, Gabrielaite M, Kjær A, Rosenfeld N, Mouliere F, Østrup O, Vogelius IR, Bentzen SM. Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. PLoS One. 2020 Apr 28;15(4):e0231884. doi: 10.1371/journal.pone.0231884. PMID: 32343749; PMCID:PMC7188247.

Nowak RG, Schumaker LM, Ambulos NP, Ndembi N, Dauda W, Nnaji CH, Mitchell A, Mathias TJ, Jibrin P, Darragh TM, Olaomi O, Crowell TA, Baral SD, Charurat ME, Bentzen SM, Palefsky JM, Cullen KJ; TRUST/RV368 Study Group. Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria. Papillomavirus Res. 2020 Dec;10:100200. doi: 10.1016/j.pvr.2020.100200. Epub 2020 May 31. PMID: 32492573; PMCID: PMC7287273.

Holtzman NG, Xie H, Bentzen SM, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183. PMID: 32750704; PMCID:PMC7850044.

Bentzen SM, Haviland JS, Yarnold JR. Targeted Intraoperative Radiotherapy for Early Breast Cancer. JAMA Oncol. 2020 Oct 1;6(10):1636. doi: 10.1001/jamaoncol.2020.2716. PMID: 32789502.

Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. PMID: 33115543; PMCID: PMC7594416.

Clausen MM, Vogelius IR, Kjær A, Bentzen SM. Multiple Testing, Cut-Point Optimization, and Signs of Publication Bias in Prognostic FDG-PET Imaging Studies of Head and Neck and Lung Cancer: A Review and Meta-Analysis. Diagnostics (Basel). 2020 Dec 1;10(12):1030. doi: 10.3390/diagnostics10121030. PMID: 33271785; PMCID: PMC7761090.

Vyfhuis MAL, Suzuki I, Bentzen SM, Cullen KJ, Goloubeva OG. Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis. Oncologist. 2021 Jul;26(7):579-587. doi: 10.1002/onco.13763. Epub 2021 Apr 15. PMID: 33783061; PMCID: PMC8265350.

Constine LS, Olch AJ, Jackson A, Hua CH, Ronckers CM, Milano MT, Marcus KJ, Yorke E, Hodgson DC, Howell RM, Hudson MM, Williams JP, Marples B, C M Kremer L, Marks LB, Bentzen SM. Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Assess Normal Tissue Radiation Dose-Volume-Response Relationships for Children With Cancer. Int J Radiat Oncol Biol Phys. 2021 Mar 16:S0360-3016(21)00129-2. doi: 10.1016/j.ijrobp.2020.10.040. Epub ahead of print. PMID: 33810949.

Anastasiadis P, Gandhi D, Guo Y, Ahmed AK, Bentzen SM, Arvanitis C, Woodworth GF. Localized blood-brain barrier opening in infiltrating gliomas with MRI-guided acoustic emissions-controlled focused ultrasound. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):e2103280118. doi: 10.1073/pnas.2103280118. PMID: 34504017; PMCID: PMC8449371.

Chan A, Bentzen SM, Rout A, Miller K. Predicting if Lung Cancer Will Relapse - The Role of Neutrophil/Lymphocyte Ratio. Hematol Oncol Stem Cell Ther. 2023 Jan 17;16(2):158-161. doi: 10.1016/j.hemonc.2021.08.003. PMID: 34562406.

Nowak RG, Bentzen SM, Schumaker LM, Ambulos NP, Ndembi N, Dauda W, Mitchell A, Mathias TJ, Crowell TA, Baral SD, Blattner WA, Charurat ME, Palefsky JM, Cullen KJ; TRUST/RV368 Study Group. Evaluating the Jaccard Similarity Index as a Persistence Measure of Multiple Anal Human Papillomavirus Among Nigerian Men Who Have Sex With Men. Sex Transm Dis. 2022 Apr 1;49(4):297-303. doi:
10.1097/OLQ.0000000000001587. PMID: 34840323; PMCID: PMC8940626.

Ward MC, Bentzen SM, Fasola CE, Khan AJ, White RL, Vicini F, Shah C. An Estimate of Local Failure in the TARGIT-A Trial of Pre-pathology Intraoperative Radiation Therapy for Early Breast Cancer. Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):73-76. doi: 10.1016/j.ijrobp.2021.12.161. Epub 2022 Jan 20. PMID: 35065848.

Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. PMID: 35091444; PMCID: PMC8976746.

Kronfli D, Savla B, Lievers A, Baker K, Eggleston C, Miller R, Bentzen SM, Mohindra P, Vyfhuis MAL. Identifying Psychosocial Needs of Patients With Cancer Undergoing Curative Radiation Therapy in an Inner-City Academic Center to Address Racial Disparities. Int J Radiat Oncol Biol Phys. 2022 Oct 1;114(2):185-194. doi: 10.1016/j.ijrobp.2022.04.003. Epub 2022 Apr 29. PMID:

Hoeben BAW, Pazos M, Seravalli E, Bosman ME, Losert C, Albert MH, Boterberg T, Ospovat I, Mico Milla S, Demiroz Abakay C, Engellau J, Jóhannesson V, Kos G, Supiot S, Llagostera C, Bierings M, Scarzello G, Seiersen K, Smith E, Ocanto A, Ferrer C, Bentzen SM, Kobyzeva DA, Loginova AA, Janssens GO. ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in children. Radiother Oncol. 2022 Aug;173:119-133. doi: 10.1016/j.radonc.2022.05.027. Epub 2022 May 31. PMID: 35661674.

Khairnar R, DeMora L, Sandler HM, Lee WR, Villalonga-Olives E, Mullins CD, Palumbo FB, Bruner DW, Shaya FT, Bentzen SM, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Albert M, Currey AD, Pisansky TM, Chen Y, Horwitz EM, DeNittis AS, Feng F, Mishra MV. Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO Clin Cancer Inform. 2022 Jun;6:e2100188. doi: 10.1200/CCI.21.00188. PMID: 35776901; PMCID:

Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J,Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24. PMID: 36001857.

Savla B, Hamza MA, Yacubovich D, Cobbs S, Petrovska L, Scilla KA, Burrows W, Mehra R, Miller RC, Rolfo C, Bentzen SM, Mohindra P, Vyfhuis MAL. The impact of Body Mass Index (BMI) and residence in Food Priority Areas (FPAs) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2023 Jan 28:S0360-3016(23)00080-9. doi: 10.1016/j.ijrobp.2023.01.032. Epub ahead of print. PMID: 36720317.

Awards and Affiliations


2024 Lifetime Achievement Award, European Society for Radiation Oncology (ESTRO)

2023 Honorary Fellow of the British Institute of Radiology

2023 Medal for Outstanding International Achievement, British Institute of Radiology

2022 Anne and Donald Herbert Distinguished Lecture on Modern Statistical Modeling, American Association of Physicists in Medicine (AAPM)

2020 Honorary life member of the German Society for Radiation Oncology (DEGRO)

2018 Fellow of the American Society for Radiation Oncology (FASTRO)

2017 Seoul National University Hospital Distinguished Lecturer, Seoul, Republic of Korea

2017 Gold Medal, American Society for Radiation Oncology (ASTRO)

2016 Gilbert H. Fletcher Distinguished Lecturer, International Conference on Translational Research in Radiation Oncology – Physics for Health in Europe, Geneva, Switzerland

2016 Danish Association for Cancer Research Honorary Award, Copenhagen, Denmark

2015 CARO Honorary Award Lecture, Canadian Association for Radiation Oncology, Kelowna, BC, Canada

2013 International KFJ Research Award, Rigshospitalet, Copenhagen, Denmark

2011 1st James Oleson Visiting Professorship, Duke University, Durham, NC, USA

2011 Royal Australian and New Zealand College of Radiologists, Keynote Lecturer, Melbourne, VIC, Australia

2011 Douglas Lea Lecture, Institute of Physics and Engineering in Medicine, UK

2009 Honorary Life Member, Belgian Society for Therapeutic Radiology and Oncology

2009 Varian Lectureship, University of Copenhagen, Denmark

2009 Alan C Burton Lecturer, University of Western Ontario, London, ON, Canada

2009 Vaeth Lectureship, San Francisco Radiation Oncology Conference, San Francisco, CA, USA

2008 Collins Lecturer, Harvard Medical School, Boston, MA, USA

2008 Honorary Life Member, Association of Radiation Oncologists of India

2008 Dr. Solomon Padam Singh Oration, Association of Radiation Oncologists of India, Mumbai, India

2008 Distinguished Alumnus Award, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

2007 Elis Berven Award Lecture, Swedish Society of Oncology

2006 Rolf Wideröe Award, Radiumhospitalet, University of Oslo, Norway 

2006 ESTRO-ICTR Translational Research Award, International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, Lugano, Switzerland

2003 Acta Oncologica Lectureship, Norwegian Society of Oncology

2003 Gold Medal (Klaas Breur Medal), European Society for Therapeutic Radiology and Oncology (ESTRO)

2003 Emmanuel van der Schueren Award Lecturer, European School of Oncology

2003 Institute of Cancer Research Distinguished Lecturer, Sutton, UK

2001 Allen S. Lichter Lectureship, University of Michigan, Ann Arbor, MI, USA

2001 Varian Lectureship, Harvard Medical School, Boston, MA, USA

1999 Royal Australian and New Zealand College of Radiologists Annual Lecturer, Sydney, NSW, Australia

1998 Clinical Oncology Award, Danish Society for Oncology, Denmark

1998 L.H.Gray Memorial Trust Lecture, Association for Radiation Research, UK


Professor, tenured, Department of Epidemiology and Public Health, primary faculty appointment, University of Maryland School of Medicine, Baltimore, MD, USA

Professor of Radiation Oncology, secondary faculty appointment, University of Maryland School of Medicine, Baltimore, MD, USA

Director, Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA

Director, University of Maryland Greenebaum Comprehensive Cancer Center Biostatistics Shared Service, University of Baltimore School of Medicine, Baltimore, MD, USA

Director, Biostatistics Core, Institute for Clinical and Translational Research, University of Maryland Baltimore, Baltimore, MD, USA

Member, University of Maryland Greenebaum Comprehensive Cancer Center, Experimental Therapeutics Program, University of Baltimore School of Medicine, Baltimore, MD, USA

Member, Graduate Faculty of the University of Maryland Graduate School, Baltimore; Affiliated with the Epidemiology and Human Genetics Program and the Molecular Medicine Program

Affiliate Member, Institute for Global Health (IGH), University of Baltimore School of Medicine, Baltimore, MD, USA

Research Associate without Compensation, Department of Veterans Affairs Medical Center, Maryland Health Care System, Baltimore, MD, USA

Adjunct Professor, Department of Oncology, University of Copenhagen, Denmark

Social Media